EXCERPT:
“We are pleased to establish Invitrocue’s first laboratory in Europe, quickly expanding the availability of Onco-PDO® to a much wider patient and physician group. Approximately one quarter of the global total of cancer cases are in Europe with some 3.7 million new patients a year. Our collaboration with Systasy enables us to deliver against our strategy to gain fast access to test facilities and scale our operations with a well-managed cost base.”
-Dr. Steven Fang, Executive Chairman
Click to read full article.
invitrocue-roll-out-onco-pdo-germany
